This facility will be close to Ablynx’s existing facilities and the company has secured the right to use 70% of the capacity of the Bio-Accelerator, which is expected to be completed by mid-2010.
Edwin Moses, CEO and chairman of Ablynx, said: “We are very pleased to have secured this agreement with the consortium. This allows us to further establish a center of excellence for Nanobody technology in Ghent and consolidate our Belgian operations in the Bio-Accelerator.
“Ablynx will have approximately 200 staff by the end of 2008 and remains on track to become one of Europe’s leading biotechnology companies, with the goal of filing five investigational new drug equivalents for our wholly owned products by 2012.”